Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Petragen Inc. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are split between 2 distinct examiners and 2 distinct art units. This indicates that each pending action is being handled by a different examiner in a different unit. This decentralized approach can be advantageous as it allows for independent review of the company's technology by 2 distinct examiners across different segments of the patent office.
SEAMAN, D MARGARET M is the busiest examiner for the company with 1 pending office action. With 2 distinct examiners each managing 1 of the 2 total pending actions, the portfolio shows no concentration of work under a single official. This distribution requires the applicant to manage separate interactions across 2 distinct art units. The strategy ensures that the outcome of one pending action is less likely to be influenced by the examiner's specific views on the other pending matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SZNAIDMAN, MARCOS L | 1 | 37.3% | +16.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18298059 | COMPOSITIONS OF ENPP1 INHIBITORS AND USES THEREOF | SZNAIDMAN, MARCOS L | 34d |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18298059 | COMPOSITIONS OF ENPP1 INHIBITORS AND USES THEREOF | SZNAIDMAN, MARCOS L | 1628 | §112 | Final Rejection | 34d | Pending | Apr 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial